Gastroenterology

Back to articles

Second IBS Medication Approved in as Many Months

KEY POINT

The approval of tegaserod maleate (Zelnorm—Novartis) for short-term management of constipation-predominant form of irritable bowel syndrome (IBS) in women brings to two the number of medications approved this summer for IBS. Tegaserod differs from the recently resurrected GlaxoSmithKline’s alosetron (Lotronex), which is indicated only for women with the diarrhea-predominant form of IBS.